|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Human JAM-A / F11R / CD321 protein (Catalog#10198-H08H)|
|10 μl/Test, 0.1 mg/ml|
|Aqueous solution containing 0.5% BSA and 0.09% sodium azide|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human JAM-A / F11R / CD321 (rh JAM-A / F11R / CD321; Catalog#10198-H08H; NP_058642.1; Met 1-Ala 242) and conjugated with PE under optimum conditions, the unreacted PE was removed.|
|Human JAM-A / F11R / CD321|
|This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze ! |
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
Profile of anti-JAM-A (CD321) reactivity on SKBR3 cells analyzed by flow cytometry.
Junctional adhesion molecule-A (JAM-A), also known as F11 receptor (F11R) or Cluster of Differentiation 321 (CD321), is a transmembrane protein expressed at tight junctions of epithelial and endothelial cells, as well as on circulating leukocytes. JAM-A protein serves as a serotype-independent receptor for mammalian orthoreoviruses (reoviruses). It is also a ligand for the integrin LFA1, involves in leukocyte transmigration. As a cell adhesion molecule of the immunoglobulin superfamily, JAM-A protein involves in platelet adhesion, secretion and aggregation, and plays a crucial role in inflammatory thrombosis and atherosclerosis. In addition, it may be a potential therapeutic target for breast cancer.